Stockscreener 앱 받기
1.37
23.42%
0.26
Cumberland Pharmaceuticals Inc 주식(CPIX)의 최신 뉴스
Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by Analysts at StockNews.com - Defense World
Cumberland Pharma stock hits 52-week low at $1.04 By Investing.com - Investing.com Nigeria
Cumberland Pharma stock hits 52-week low at $1.04 - Investing.com
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2024 Earnings Call Transcript - MSN
Corneal Ulcer Treatment Market 2034: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail
StockNews.com Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX) - Defense World
Ibuprofen Injection Shows Better Real-World Outcomes in Comparative Study - Pharmacy Practice News
Cumberland Pharma stock hits 52-week low at $1.07 - Investing.com
Cumberland Pharma stock hits 52-week low at $1.07 By Investing.com - Investing.com UK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Cumberland Partners Ltd - MarketBeat
Ibuprofen injection exhibits kidney safety with cost benefits over ketorolac: Study - Medical Dialogues
Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023) - Yahoo Finance UK
Cumberland Pharmaceuticals Inc. (CPIX) Quarterly 10-Q Report - Quartzy
Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ... By GuruFocus - Investing.com Canada
Cumberland: Q3 Earnings Snapshot - mySA
Cumberland Pharmaceuticals Reports Q3 2024 Earnings and Developments - TipRanks
Cumberland Pharmaceuticals Inc (CPIX) Reports Q3 2024 Revenue of $9.1 Million and EPS Loss of $0.11 - GuruFocus.com
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update - StockTitan
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire UK
Cumberland's Ifetroban Secures Dual FDA Designations for Rare DMD Treatment | CPIX Stock | CPIX Stock News - StockTitan
Cumberland Pharmaceuticals director James Jones buys $1,827 in stock - Investing.com
Cumberland Pharmaceuticals CEO A.J. Kazimi buys $1,827 in stock - Investing.com
Cumberland Pharmaceuticals director Caroline Young acquires $913 in stock - Investing.com
Cumberland Pharmaceuticals director James Jones buys $1,827 in stock By Investing.com - Investing.com UK
Cumberland's Caldolor Shows 78% Better Safety Than Ketorolac in Landmark 150K Patient Study | CPIX Stock News - StockTitan
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS - Citizentribune
Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight - PR Newswire UK
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt? - Simply Wall St
Cumberland Pharma stock hits 52-week low at $1.18 By Investing.com - Investing.com Australia
Cumberland Pharma stock hits 52-week low at $1.18 - Investing.com India
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size, Share Analysis And Growth Statistics By 2033 - WhaTech
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - India Shorts
Bacterial Pneumonia Market Expected to See Prominent Growth - openPR
Complicated Skin And Skin Structure Infections Drugs Market Insights Discussed Regarding Share, Trends, Siz... - WhaTech
Idiopathic Pulmonary Fibrosis Ipf Market Size and Growth - openPR
Scleroderma Market to Witness Significant Growth by 2031 | Pfizer, Inc., Sanofi, GlaxoSmithKline plc - openPR
Cumberland Pharma stock hits 52-week low at $1.19 By Investing.com - Investing.com Australia
Cumberland Pharma stock hits 52-week low at $1.19 - Investing.com
Vasopressin Market Huge Growth in Future Scope 2024-2031 | Par - openPR
Shareholders have faith in loss-making Phathom Pharmaceuticals (NASDAQ:PHAT) as stock climbs 6.6% in past week, taking one-year gain to 74% - Simply Wall St
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
Cumberland Pharmaceuticals (NASDAQ:CPIX) Research Coverage Started at StockNews.com - Defense World
Scleroderma Diagnostics and Therapeutics Market – 37% of Growth to Originate from APAC -Actelion Pharmaceuticals, Inc., – உங்கள் குரல் - உங்கள் குரல்
Cooling Paste Market Growing Rapidly by-Kobayashi Pharmaceutical, Hisamitsu Pharmaceutical, Pigeon, New Tac Kasei, Sato – IndiaPolitics.com - IndiaPolitics.com
Ibuprofen Injection Industry to Witness Massive Growth (2024-2034) |Cumberland Pharmaceuticals, CSL Limited, Akorn, Inc. – IndiaPolitics.com - IndiaPolitics.com
Cooling Paste Industry to Witness an Outstanding Growth by 2030 |Kobayashi Pharmaceutical, Hisamitsu Pharmaceutical, Pig – IndiaPolitics.com - IndiaPolitics.com
Drugs for Xerostomia Market Future Developments – Concordia, AMICI, Aurobindo Pharma Ltd, Impax Labs - Cauverynews
Burn Pain Market Expected to Experience Major Growth by 2034, - openPR
0.83%
1.03%
자본화:
|
볼륨(24시간):